Європейський Союз - хорватська - EMA (European Medicines Agency)

accord healthcare s.l.u. - abirateron acetat - prostatske neoplazme - endokrinska terapija - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Європейський Союз - хорватська - EMA (European Medicines Agency)

mylan ireland limited - abirateron acetat - prostatske neoplazme - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Європейський Союз - хорватська - EMA (European Medicines Agency)

krka, d.d., novo mesto - abirateron acetat - prostatske neoplazme - endokrinska terapija - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Європейський Союз - хорватська - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - modificirane žive goveđa virusni proljev virus tipa 1, sobe-цитопатического roditeljske soja ke-9 i pms-om živi goveđa virusni proljev virus tipa 2, ne цитопатического roditeljske soja new york-93 - imunomodulatori za bika, živa virusna cjepiva - za aktivna imunizacija goveda od 3 mjeseca starosti, a za smanjenje гипертермии i kako bi se smanjili smanjenje broja bijelih krvnih stanica uzrokovana virusne dijareje goveda (bvdv-1 i bvdv-2), i smanjiti izlučivanje virusa i вирусемии uzrokovane bvdv-2. za aktivnu imunizaciju goveda protiv bvdv-1 i bvdv-2, kako bi se spriječilo nastanak uporno zarazenih teladi uzrokovanih transplacentalnom infekcijom.

Європейський Союз - хорватська - EMA (European Medicines Agency)

novartis europharm limited - trametinib - melanoma - antineoplastična sredstva - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 i 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. Немелкоклеточный rak pluća (НМРЛ)trametinib u kombinaciji s dabrafenib indiciran za liječenje odraslih bolesnika s preliminarnim non-mali raka pluća stanice s Браф mutacija v600 daleko .

Європейський Союз - хорватська - EMA (European Medicines Agency)

mendelikabs europe ltd - nitisinone - tyrosinemias - drugi gastrointestinalni trakt i metabolizam, lijekovi, - liječenje odraslih i pedijatrijskih (u bilo kojoj dobnoj skupini) bolesnika s potvrđenom dijagnozom nasljedne tirozinemije tip 1 (ht1) u kombinaciji s prehrambenim ograničenjem tirozina i fenilalanina.

Хорватія - хорватська - HALMED (Agencija za lijekove i medicinske proizvode)

sandoz d.o.o., maksimirska 120, zagreb - epirubicinklorid - otopina za injekciju/infuziju - 2 mg/ml - urbroj: jedan mililitar (ml) otopine sadrži 2 mg epirubicinklorida

Хорватія - хорватська - HALMED (Agencija za lijekove i medicinske proizvode)

hospitalija trgovina d.o.o., sveta nedelja - aparat za fizioterapiju

Європейський Союз - хорватська - EMA (European Medicines Agency)

advanced accelerator applications - l-arginine hydrochloride, l-lysine hydrochloride - Лучевые oštećenja - detoxifying agents for antineoplastic treatment - lysakare indiciran za smanjenje izloženosti zračenju kada bubrega peptid-рецепторного радионуклидной terapije (prrt) s Лютеций (177lu) oxodotreotide kod odraslih.

Боснія і Герцоговина - хорватська - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

amicus pharma d.o.o. - askorbinska kiselina, kalijumhlorid, makrogol, natrijumaskorbat, natrijumhlorid, natrijumsulfat - prašak za oralni rastvor - 100 g/1 kesica+ 7.5 g/1 kesica+ 2.691 g/1 kesica+ 1.015 g/1 kesica+ 4.7 g/1 kesica+ 5.9 g/1 kesica - 1 pakovanje praška za oralni rastvor (vrećice a i b) sadrži: vrećica a 100,00 g makrogola, 7,500 g natrijumsulfata, bezvodnog, 2,691 g natrijumhlorida, 1,015 g kalijumhlorida; vrećica b sadrži 4,700 g askorbinske kiseline i 5,900 g natrijumaskorbata